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Abstract Background There is an unstable balance between pro- and anti-haemostatic processes
in patients with cirrhosis. We hypothesized, that in patients with acute decompensation
(AD) the major alterations of von Willebrand factor (VWF) could contribute to the pro-
thrombotic situation as compared to patients with stable (ST) cirrhosis.
Patients and Methods We analysed different parameters of VWF, including detailed
multimer distribution by densitometry and platelet adhesion, together with a disin-
tegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13)
activity and antigen and C-reactive protein (CRP) levels in patients with ST cirrhosis
(n ¼ 99), with AD (n ¼ 54) and controls (n ¼ 92).
Results VWF antigen, ristocetin co-factor as well as collagen-binding activities were
elevated in both cirrhotic groups in a stepwise manner. There was a decrease in high and
an increase in lowmolecularweightmultimer ratios in themajorityofSTcirrhosis.However, in
24 out of 54 AD patients, ultra-large VWFmultimers (ultra-largemolecular weightmultimers
[ULMWM]) were found. ADAMTS13 activity in ST and AD patients without ULMWM was
similar to controls (median [interquartile range; IQR]%: 98 [67–132] and 91 [60–110] vs. 106
[88–117], respectively). The presence of ULMWM in AD patients was associated with low
ADAMTS13 activity [33 (24–49)%] and high CRP level [23 (7.1–83.6) mg/L]. Adhesion of
normalplatelets showedastepwise increase in thepresenceofcirrhotic plasmas, reaching the
highest level in AD patients with ULMWM.
Conclusion Characteristic changes of VWF parameters are seen in ST cirrhosis. In AD
patients, highly increasedVWFand reducedADAMTS13activitycouldbe found, alongwith the
presence of ULMWM,which are possiblemarkers and contributors of the disease progression.
 These authors contributed equally to this work and should be
considered as first authors.
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Introduction
von Willebrand factor (VWF) is a large, multimeric protein,
playing a central role in platelet adhesion and primary
haemostasis. The level of VWF is increased in patients with
cirrhosis and correlates with the severity of the disease.
There is a tightly regulated balance between pro-haemo-
static and anti-haemostatic processes, and this might actu-
ally also be maintained in patients with cirrhosis.1,2 Platelet
abnormalities can be compensated by elevated VWF levels as
was suggested previously.3,4 There are studies where also a
close correlation of VWF level and portal hypertension as
well as mortality has been described.5,6
The activity of VWF is strictly regulated by the VWF-
cleaving protease a disintegrin-like and metalloproteinase
with thrombospondin type-1 motifs 13 (ADAMTS13), as the
reactivity of VWF towards platelets is proportional to its
multimeric size.7 In patients with either congenital or
acquired deﬁciency of ADAMTS13, ultra-large VWF multi-
mers are present leading to thrombotic micro-angiopathy,
for example, thrombotic thrombocytopenic purpura (TTP).8
ADAMTS13 is synthesized by hepatic stellate cells9,10 that are
generally activated in liver cirrhosis.11 Previously variable
activity and antigen levels of ADAMTS13 have been reported
in patients with liver cirrhosis. Mannucci et al12 and Feys et
al13 discovered that ADAMTS13 activity is signiﬁcantly
reduced in advanced liver disease.
The previously demonstrated pro-thrombotic tendency,
endothelial dysfunction together with systemic inﬂamma-
tion and bacterial infections can play a major role in the
worsening of cirrhosis.14–18 The development of bacterial
infections like spontaneous bacterial peritonitis, hepatic
encephalopathy (HE), gastrointestinal (GI) bleeding and/or
rapid accumulation of ascites in patients with previously
stable disease are collectively referred to as acute decom-
pensation (AD) as was deﬁned in the CANONIC study.19
There are no solid data, however, about the characteristics
of VWF parameters, like antigen level, functional activity,
multimeric structure as well as ADAMTS13 in cirrhotic
patients with AD as compared to stable (ST) cirrhosis. Since
VWF is an acute phase protein, the alterations of this multi-
meric protein as well as ADAMTS13 seem to be important
especially in an already rebalanced situation.
In this study, we aimed to analyse the quantitative para-
meters of VWF, including VWF antigen (VWF:Ag) and pro-
peptide (VWFpp) levels, VWF ristocetin co-factor activity
(VWF:RCo), collagen-binding activity (VWF:CB) as well as
ADAMTS13 antigen and activity levels in controls and in
patients with cirrhosis either in a stable outpatient cohort or
hospitalized due to AD. Furthermore, we performed a quanti-
tative multimeric analysis of VWF as well as platelet adhesion
assay in the plasma of these patients. Sincebacterial infections
that elicit acute phase reactions are frequent in our cirrhotic
patients,15,20–22wealsoconsideredtheassociationof systemic
inﬂammation and VWF parameters. We wanted to clarify the
effect of AD and systemic inﬂammation in patients with
cirrhosis onVWFparameters aswell as onADAMTS13 activity.
Furthermore,wewanted to seewhether thepresence of a pro-
thrombotic state can be conﬁrmed in these patients, which
also can contribute to the disease progression.
Patients and Methods
Patients
One hundred ﬁfty-three well-characterized patients with
cirrhosis of various causes were included consecutively from
our in- and outpatient gastroenterology department into
this study. The female/male ratio was 75/78, and the median
agewas 56 (range: 24–80) years. The diagnosis was based on
clinical, biochemical and imaging investigations as well as on
liver biopsy when available. The aetiology of cirrhosis was
alcoholic liver disease (n ¼ 106), chronic viral hepatitis C or B
(n ¼ 34) and others, like primary biliary cholangitis (pre-
viously cirrhosis), autoimmune hepatitis or cryptogenic cir-
rhosis (n ¼ 13). This cohort comprises 99 outpatients with
ST cirrhosis and 54 hospitalized subjects due to an AD
episode. There was no patient included into both groups
due to disease progression. The presence of acute-on-chronic
liver failure (ACLF) was evaluated retrospectively within the
AD group (i.e. additional presence of organ failure(s)), after
its deﬁnitionwas published in the CANONIC study.19 Patients
with hepatocellular carcinoma were excluded, as it can
inﬂuence the levels of VWF:Ag and ADAMTS13.23,24 None
of the patients enrolled to this study received fresh frozen
plasma, blood transfusion or platelet concentrate, nor did
they use aspirin or any non-steroidal anti-inﬂammatory
drugs for 2 weeks prior to the time of inclusion. Ninety-
two healthy age-matched volunteers served as controls.
Methods
Blood samples obtained by venipuncture from the antecu-
bital vein into 3.2% sodium citrate (9:1, v/v) were centrifuged
twice (2,000  g for 15 minutes), snap frozen in aliquots and
stored at –70°C until use.
C-reactive protein (CRP)was determined using the Integra
700 automated analyzer system (Roche, Basel, Switzerland),
where 10mg/L cut-off value—proved to be themost accurate
for prediction of infection-free survival,15 and therefore we
used this level in this trial.
VWF:Ag was determined using polyclonal antibody against
VWF for coating and its horseradish peroxidase-labelled pro-
duct for detection in an enzyme-linked immunosorbent assay
(ELISA).25 Both antibodies were purchased from Dako
(Glostrup, Denmark). VWF:CB was determined as was
described in our previous publication.26 In short, human type
III collagen (Sigma-Aldrich, St. Louis, Missouri, United States),
20 μg/mL in sodium phosphate-buffered saline (PBS), pH 7.4
was used for coating, followed bywashing with PBS containing
0.1% Tween-20 (PBS-T). Each well was then incubated with
100µLofplasmadilutedinPBS-Tat roomtemperature.VWF:Ag
and VWF:CB measurements were performed in parallel using
the same plasma dilutions. The amount of VWF bound to
collagen was detected using the same horseradish peroxi-
dase-labelled polyclonal antibody against VWF (Dako). The
World Health Organisation (WHO) 2nd International Standard
von Willebrand Factor, Concentrate, National Institute for
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Biological Standards and Control (NIBSC) code: 09/182 was
used for calibration of these methods (NIBSC, UK). VWF:RCo
was determined by using Ristocetin reagent that contained
lyophilized platelets (Helena BioSciences, Sunderland, UK) in a
Chrono-Log 810-CA lumi-aggregometer (Chronolog, Haver-
town, Pennsylvania, United States). VWFpp levelwasmeasured
by ELISA kit using mouse antibody pair clones CLB-Pro 35 and
CLB-Pro 14.3 (Cell Sciences, Canton, Massachusetts, United
States), according to the manufacturer’s instruction.
ADAMTS13 activity was determined by ﬂuorescein reso-
nance energy transfer analysis,27 using the TECHNOZYME
ADAMTS-13 kit (Technoclone, Vienna, Austria), according to
the instruction of themanufacturer. ADAMTS13 antigen levels
weremeasuredbyELISAaspreviouslypublished.13ADAMTS13
antigen level in pooled normal plasma was set at 100%.
Multimeric analysis of VWF was determined as previously
described.28 Brieﬂy, VWFmultimers were separated by sodium
dodecyl sulphate (SDS) 0.8% agarose gel electrophoresis, fol-
lowed by Western blotting. Bands were visualized by horse-
radish peroxidase-labelled polyclonal antibody against VWF
(Dako) and 3,3’-diaminobenzidine substrate (Sigma-Aldrich).
The ﬁrst 5 bands were considered as low, bands 6 to 10 as
intermediate and larger than 10, including the areawhere VWF
did not resolve into bands, as high molecular weight multimers
(LMWM, IMWM, HMWM), respectively, as was previously
described.29 Digital images of the bands were obtained by a
GS-800 calibrated densitometer and processed by its Quanti-
tyOne software (Bio-Rad Laboratories, Richmond, California,
United States). The proportions of the three groups of bands
were calculated from the area under the curve (AUC), con-
structed for all bands. Additionally, all samples were separated
on 0.65% gels too and visually analysed for the presence of ultra-
large molecular weight multimers (ULMWM) within the
HMWM. ULMWM were deﬁned as the high molecular weight
bands not seen in controls.29 The quantity of VWF within each
group of multimers was calculated by multiplying the relative
ratios of the low, intermediate or high MWMs with the total
VWF:Ag level.
The ability of plasma from 10 ST and 10 AD patients with
cirrhosis aswell as10controls to support platelet adhesionwas
studied under ﬂow conditions using reconstituted blood.30
Cellular elements of the reconstituted blood were isolated
from healthy, O blood group donors. Adhesion study was
completedwithin2hoursafter venipuncture. Platelet adhesion
onto an uncoated polystyrene surfacewas carried out using an
Impact-R cone and plate analyser (CPA; DiaMed, Switzer-
land).31 Platelet adhesion was quantiﬁed using acid phospha-
tase assay.32 Method details are the following. Citrated blood
was centrifuged to obtain platelet-rich plasma (PRP, 150 g,
10 minutes, 25°C). Both the separated PRP and the remaining
fraction of the bloodwere further centrifuged for platelet-poor
plasma (PPP, 2,000 g, 10 minutes, 25°C). After removing the
PPP, thecellular partsweresuspended inHEPESbufferedsaline,
containing0.0129 Msodiumcitrate, 0.005 MD-glucose and40
g/L bovine serum albumin (suspension buffer) to the original
blood volume. Aliquotswere pipetted into Eppendorf tubes for
each adhesion experiment to obtain a platelet count of 200 g/L
and a haematocrit of 0.37 in a ﬁnal volume of 0.14 mL
reconstituted blood. After a washing step (centrifugation at
2,000  g, 10 minutes, 25°C), the supernatant was removed
and the cells were suspended with the different cirrhotic or
control plasmas to a ﬁnal volume of 0.14 mL. Reagents were
purchased from Sigma-Aldrich, Germany. For the adhesion,
0.13mL of this reconstituted bloodwas pipetted into thewells
and submitted at a shear rate of 1,800/s for 2.5 minutes. Each
well of the CPA was gently washed ﬁve times with PBS to
remove unbound platelets and all compartments of the blood.
Bound platelets were then lysed with 0.2 mL of lysis buffer
containing acid phosphatase substrate: 0.1 M citrate-phos-
phate buffer (pH 5.4), 0.1% Triton X-100, 0.01 M p-nitrophenol
phosphate.Wells were incubated for 1 hour at 37°C in a humid
box incubator and rotated continuously. Out of this mixture,
0.15 mL was added to 0.05 mL 2 N NaOH into a 96-well plate
to stop the enzyme reaction. The resultant colour was read at
405/545 nm and the number of the adhered platelets was
calculated by the aid of the standard curve, which was con-
structed inparallel using theoriginalplatelet suspension. Intra-
assay coefﬁcient of variation for the adhesion results was 12%.
For the thrombin generation assay (TGA) citrated blood
sampleswere centrifuged at 20°C for 15minutes at 3,200  g
within 1 hour of venipuncture. Plasma was separated and
centrifuged again (3,200  g, 10 minutes), and aliquots of
the supernatant were stored at –70°C. Analysis was per-
formedwithin 3 weeks. Individual aliquots were thawed in a
37°C water bath by tilting for 15 minutes, vortex mixed for
5 seconds and sampled immediately into black 96-well
plates (Greiner GmbH, Germany). TGAwere carried out using
the Technothrombin TGA kit with ﬂuorescent substrate and
reagent C (50 pM tissue factor [TF] and low concentration of
phospholipid) according to the manufacturer’s instructions.
The reader, the plate with plasma and the reagent/substrate
mixture were pre-heated to 37°C, and then 0.06 mL reagent/
substrate mixture was added to 0.04 mL of plasma. The
enzyme reaction was initiated by TF at a ﬁnal concentration
of 5 pM and detected with a BIOTEK Flx800 reader. Relative
ﬂuorescence units measured by the ﬂuorimeter were con-
verted into peak thrombin concentration (nM). A reference
curve was constructed using a thrombin standard calibrated
against the thrombin reference preparation of theWHO. The
TGA kits, the Reader and the software were from Techno-
clone GmbH.
Ethical Considerations
The study design was approved by the Regional and Institu-
tional Research Ethics Committee (DEOEC RKEB/IKEB 5306-
9/2011). Each patient was informed of the nature of this
study and signed an informed consent.
Statistical Analysis
Variables were tested for normality using Shapiro–Wilk’s W
test. Continuous variables were summarized as medians and
interquartile range (IQR; 25–75th percentiles). Categorical
variables were comparedwith Fisher’s exact test or chi-square
testwithYates correction, as appropriate. Continuous variables
were comparedwithMann–Whitney U-test or Kruskal–Wallis
H test with Dunn’s multiple comparison post hoc analysis. The
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Spearman’s non-parametric rank correlation test was used to
determine correlations. To discriminatebetween survivors and
non-survivors, the receiver operating characteristic (ROC)
curve was used. AUC and corresponding 95% conﬁdence inter-
vals (CIs)werecalculated.Youdenindexwaschosen toestimate
the best discriminate threshold. Kaplan–Meier survival curves
were plotted to estimate the cumulative probability of 6-
monthsurvivalofpatients. For statistical analysis andgraphical
presentation, SPSS 24.0 (SPSS, Chicago, Illinois, United States)
and GraphPad Prism 6 (San Diego, California, United States)
programs were used. A two-sided probability value of < 0.05
was considered to be statistically signiﬁcant.
Results
Baseline Characteristics
Of 99 ST cirrhosis patients included, 51 had Child-Pugh A stage,
43hadChild-PughBand5hadChild-PughCcirrhosis. At timeof
enrolment, 10 patients had stable chronic renal impairment,
with creatinine level between 135 and 329 µmol/L. AD events
were deﬁned as either bacterial infection, or HE, or sudden
worseningofascitesorupperGIbleeding. Themajorityof the54
AD patients had advanced cirrhosis, Child-Pugh B/C stage, but 6
patients had early Child-Pugh A cirrhosis. Thirty patients out of
54 had bacterial infection, with tense ascites in 17 patients, HE
in 5 patients and upper GI bleeding in 5 patients. Out of the 24
patients without bacterial infection, 12 had upper GI bleeding
(among them the 6 patients with Child-Pugh A stage), 8 had
tense ascites and 6 had HE as the leading cause of AD. Out of 54
AD patients, 28 hadmore than one event simultaneously. ACLF
was detected only in 17 AD patients, grade 1 in 10, grade 2 in 5
andgrade 3 in 2 patients, respectively. Clinical characteristics of
patients at inclusion are presented in ►Table 1.
VWF:Ag and Its Functional Activity Levels
In cirrhosis, VWF:Ag, VWF:RCo level and VWF:CB activity
was higher compared to healthy controls, see ►Fig. 1A–C.
Patients with AD had even higher values than patients with
Table 1 Epidemiologic, clinical and laboratory characteristics of patients with cirrhosis
Patients with
stable cirrhosis
n ¼ 99
Patients with acute
decompensation
n ¼ 54
p-Value
Gender (male/female) 47/52 31/23 n.a.
Age (y)a 57 (24–75) 57 (33–80) 0.698
Aetiology, n (%) Alcohol 63 (63.6) 43 (79.6) 0.099
Viral 27 (27.3) 7 (13.0)
Other 9 (9.1) 4 (7.4)
Child-Pugh stage, n (%) A
B
51 (51.5)
43 (43.4)
6 (11.1)
24 (44.4)
< 0.001
C 5 (5.1) 24 (44.4)
MELD score 12 (9–14) 16 (12–23) < 0.001
White blood cell count (g/L)a 5.3 (4.2–6.8) 7.1 (4.6–11.0) 0.003
Platelet count (g/L)a 112 (70–161) 108 (71–165) 0.924
Serum sodium (mmol/L)a 141 (138–143) 138 (134–141) 0.001
Serum creatinine (μmol/L)a 64 (54–84) 75 (50–133) 0.122
C-reactive protein (mg/L)a 3.8 (1.5–9.0) 18.1 (6.0–48.5) < 0.001
Serum bilirubin (μmol/L)a 31 (19–50) 61 (31–179) < 0.001
Aspartate aminotransferase (U/L)a 51 (33–83) 67 (45–125) 0.002
Alanine aminotransferase (U/L)a 33 (21–57) 31 (21–58) 0.887
Serum albumin (g/L)a 37 (33–41) 28.5 (24–32) < 0.001
INRa 1.1 (1.2–1.3) 1.4 (1.2–1.7) < 0.001
Ascites present, n (%) 41 (41.4) 38 (70.0) 0.001
Patients with acute
decompensation,
n (%)
Tense ascites formation 25 (46.3) n.a.
Upper GI bleeding 17 (31.5) n.a.
HE 11 (20.4) n.a.
Bacterial infection 30 (55.6) n.a.
Six-month mortality, n (%) 4 (4.0) 17 (31.5) < 0.001
Abbreviations: GI, gastrointestinal; HE, hepatic encephalopathy; INR, international normalized ratio; MELD, model for end-stage liver disease; n.a.,
not applicable.
aMedian, interquartile range.
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ST (VWF:Ag % AD vs. ST: 371 [275–513] vs. 269 [228–323],
p ¼ 0.003; VWF:RCo % AD vs. ST: 180 [148–294] vs. 148 [128–
192], p ¼ 0.035 and VWF:CB AD vs. ST: 335 [245–405] vs. 201
[156–269], p ¼ 0.001).
Although both types of functional activities of VWF were
elevated in each group of patients, they did not reach the
level of VWF:Ag. The VWF:RCo/VWF:Ag ratio in the control
group was 0.84 (0.72–0.98), whereas it was lower in both
cirrhotic groups. In ST patients 0.55 (0.48–0.70) and in AD
patients 0.53 (0.41–0.72) was found (►Fig. 1E). The VWF:CB/
VWF:Ag ratio was also reduced in both patient groups with
cirrhosis. In ST patients 0.79 (0.65–0.93) and in AD patients
0.83 (0.73–0.93), whereas in controls 0.92 (0.85–1.00) could
be obtained (►Fig. 1F).
A moderate correlation was found between VWF:Ag and
VWF:RCo (r ¼ 0.521, p < 0.001), and strong correlation
Fig. 1 Plasma von Willebrand factor antigen (VWF:Ag), pro-peptide (VWFpp) and VWF functional activities in cirrhosis. VWF:Ag (A), VWF
ristocetin co-factor activity (VWF:RCo) (B), VWF collagen-binding activity (VWF:CB) (C),VWFpp (D), VWF:RCo/VWF:Ag (E) and VWF:CB/VWF:Ag
(F) in plasma of healthy controls and patients with stable (ST) cirrhosis and acute decompensation (AD) are shown. VWF:Ag, VWFpp and VWF
activity levels are expressed as percentage of pooled normal plasma. Lines denote median values, boxes represent 25th to 75th percentiles and
whiskers indicate the 5th to 95th range. p-Values were calculated by Kruskal–Wallis H test with Dunn’s multiple comparison post hoc analysis.
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between VWF:Ag and VWF:CB (r ¼ 0.835, p < 0.001) as well
as VWF:CB and VWF:RCo (r ¼ 0.619, p 0.001) in cirrhosis.
In both cirrhotic groups, the level of VWFpp (►Fig. 1D)
was higher as compared to the controls. In the ST group, 222
(169–260)%, in AD patients 257 (196–323)%, while in the
controls 108 (99–121)% levels were found.
VWF:Ag levels within the AD group signiﬁcantly differed
between patients with (475 [355–649]%) and without (350
[266–446]%) ACLF (p ¼ 0.013).
Analysis of VWF Multimers
SDS agarose electrophoretic pattern of VWF and the corre-
sponding densitometric curves of plasma samples from
patients with ST or AD disease and controls are shown
in ►Fig 2. According to the visual analysis (►Fig. 2A and
►Supplementary Fig. S1, available in the online version), the
presence of ULMWM could be identiﬁed in 39 (25.5%)
patients with cirrhosis. The majority of them was in the
AD group (25 out of 54 patients, 46.3%), while 14/99 (14%)
were found in the ST group. Computerized analysis of the
densitometric curves (►Fig. 2B) was next performed, and
from the total AUC, the relative ratios of the LMWM, IMWM
and HMWM were determined, respectively. We further
analysed the samples according to the presence of ULMWM.
The ratios of the LMWMs are shown in ►Fig. 3A. It was 0.28
(0.25–0.31) in controls and the ratios were higher in both ST
and AD patients with or without ULMWM. In the samples
without ULMWM, we measured 0.38 (0.35–0.42) and 0.39
(0.32–0.46) LMWMs, for ST and AD patients, respectively. In
patients with ULMWM, the proportion of LMWM decreased
to 0.32 (0.26–0.36) in ST and 0.32 (0.29–0.36) in AD patients
but both ratios remained higher than the controls (p ¼ 0.018
and p < 0.001, respectively). The proportions of the IMWM
(►Fig. 3B) did not show any difference between the ST group
and the controls. However, in patients with AD, both with
and without ULMWM, the ratios were signiﬁcantly lower as
compared to either controls or ST. Analysing the multimer
proportions within the HMWM fraction (►Fig. 3C), we
observed 0.4 (0.37–0.44) in controls, whereas we detected
only 0.30 (0.25–0.34) and 0.29 (0.24–0.39) in patients with-
out ULMWMin ST andADpatients, respectively. Remarkably,
in patients with ST as well as AD in the presence of ULMWM
the ratios of HMWM were higher and became similar to
controls, 0.37 (0.31–0.43) and 0.40 (0.32–0.44), respectively.
The absolute amounts of VWF measured within the
different fractions of the multimers are shown in ►Fig. 3D
and E. We would like to emphasize that within the HMWM
group in the presence of ULMWM a signiﬁcantly higher
quantity of VWF:Ag was detected in both ST and AD patients.
ADAMTS13 Antigen and Activity Levels
In patients with AD, ADAMTS13 activity level was decreased
comparedtoSTandhealthycontrols (57 [29–94]vs. 98 [67-132]
and 106 [67–117]%, p < 0.001 for both).
Similarly, low ADAMTS13 antigen levels were detected in
patients with AD compared to ST and controls (66 [43–101]
vs. 120 [89–155] and 101 [91–115]%, respectively, p < 0.001
for both).
We further analysed the ADAMTS13 activity and antigen
levels, according to the presence of ULMWMwithin both the
cirrhotic groups (►Fig. 4). In patients without ULMWM,
ADAMTS13 activity levels were not different from controls,
in ST 104 (71–137)% and in AD 91 (60–110)% were found. In
patients with ULMWM, the values were signiﬁcantly lower
as compared to controls and thosewithout ULMWM. In ST 65
(51–99)% and in AD 33 (24–49)% were measured. Similar
alterations were observed for the ADAMTS13 antigen levels,
except, that in ST patients without ULMWM, the level was
higher than in the controls. In both patient groups with
ULMWM, the antigen levels were signiﬁcantly lower, than in
patients without ULMWM. In the AD group, ADAMTS13
activity level in the presence or absence of ACLF was 49
(29–68)% and 70 (44–107)%, respectively (p ¼ 0.171).
We also analysed the correlation between the quantity of
VWF:Ag calculated within the HMWM fraction and
ADAMTS13 activity in ST and AD cirrhotic patients as well
as in controls. As is shown in ►Fig. 5, a negative correlation
(Spearman’s r ¼ –0.43, p ¼ 0.01) was found between these
Fig. 2 Multimeric pattern of von Willebrand factor (VWF) after
separation on 0.8% agarose gel and the corresponding densitometric
curves. (A) Characteristic plasma sample of a patient with acute
decompensation (AD), stable (ST) cirrhosis and healthy control. The
presence of ultra-large molecular weight multimers (ULMWM) is seen
in the sample of the AD patient. No ULMWM can be seen in the sample
of ST cirrhosis or healthy control. The dotted lines across the lanes
represent critical separation on the distribution ladder according to
the number of the corresponding bands. The critical separation lines:
#1 ¼ 1 dimer; #6 ¼ 6 dimers and #10 ¼ 10 dimers. Dimers < 6 are
deﬁned as low molecular weight multimers (LMWM), dimers between
6 and 10 deﬁned as intermediate molecular weight multimers
(IMWM) and dimers > 10 deﬁned as high molecular weight multimers
(HMWM) including ULMWM. (B) The corresponding densitometric
curves indicated with different lines and areas as marked at the
bottom of A.
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Fig. 3 Proportions of the low molecular weight multimers (LMWM), intermediate molecular weight multimers (IMWM) and high molecular
weight multimers (HMWM) groups of bands and the corresponding absolute amount of vonWillebrand factor (VWF) in each group of multimers.
(A) The proportion of the area under the curve (AUC) of the ﬁrst 5 bands considered as LMWM (1–5 dimers). (B) The proportion of the AUC of
bands between 6 and 10 named as IMWM (6–10 dimers). (C) The proportion of the AUC of larger than 10 multimers, considered as HMWM
including the area where VWF did not resolve into bands anymore (> 10 dimers, HMWM). (D–F) The absolute amount of VWF within the LMWM,
IMWM and HMWM groups of multimers. The group of stable (ST) and acute decompensation (AD) patients are separated according to the
presence or absence of ultra-large molecular weight multimers (ULMWM). Lines denote median values, boxes represent 25th to 75th percentiles
and whiskers indicate the 5th to 95th range. p-Values were calculated by Kruskal–Wallis H test with Dunn’s multiple comparison post hoc
analysis.
Fig. 4 Plasma a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity (A) and antigen level (B) in
plasma of healthy controls and patients with stable (ST) cirrhosis and acute decompensation (AD) separated according to the presence of ultra-
large molecular weight multimers (ULMWM). ADAMTS13 activity and antigen levels are expressed as percentage of pooled normal plasma. Lines
denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the 5th to 95th range. p-Values were calculated by
Kruskal–Wallis H test with Dunn’s multiple comparison post hoc analysis.
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parameters in AD patients, that is, the lower the ADAMTS13
activity was, the higher the VWF:Ag level was found in the
HMWM fraction. However, in ST patients (Spearman’s r ¼
–0.18, p ¼ 0.073), as well as in the controls there was no
signiﬁcant correlation (Spearman’s r ¼ –0.043, p ¼ 0.722).
We then investigated the association between ADAMTS13
activity and systemic inﬂammation, represented by CRP, in all
AD patients. Patients with ADAMTS13 activity less than 50%
(calculatedbyROCanalysis andYouden index), hadhigherCRP
levels compared to those with ADAMTS13 activity above 50%
(29.8 [6.6–97.4] vs. 10.9 [7.1–34.5] mg/L; p ¼ 0.048). In line
with this, in AD patients with ULMWM the CRP level was
higher as compared to the ones without ULMWM (22.96 [7.1–
83.6] vs. 10.9 [4.8–36.8] mg/L; p ¼ 0.078).
Platelet Adhesion Assay
As shown in►Fig. 6A, adhesion of normal platelets showed a
stepwise increase in the presence of cirrhotic plasmas, reach-
ing the highest level in AD patients with ULMWM. VWF:Ag
level was 106 (86–120)% in controls, 309 (279–327)% in ST
and 356 (265–384)% in AD patients. VWF:Ag levels in the
absence (n ¼ 14) or presence (n ¼ 6) of ULMWM in cirrhotic
patients, were 305 (261–348)% and 340 (298–384)%, respec-
tively. The VWF:Ag levels were not signiﬁcantly different.
Thrombin Generation Assay
As shown in ►Fig. 6B, peak thrombin concentration was
increased in both cirrhotic groups as compared to controls.
We measured 192 (158–238) nM in controls (n ¼ 31), 271
Fig. 5 Linear regression line and correlation between the quantity of von Willebrand factor (VWF) high molecular weight multimers (HMWM)
and a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity. HMWM VWF antigen (VWF:Ag) levels
were plotted versus the plasma ADAMTS13 activities of healthy controls (A), Spearman’s r ¼ –0.043, p ¼ 0.722, n ¼ 70; stable cirrhosis patients
(B), Spearman’s r ¼ –0.18, p ¼ 0.073, n ¼ 98; and patients with acute decompensation (C), Spearman’s r ¼ –0.43, p ¼ 0.01, n ¼ 54.
Fig. 6 Prothrombotic tendency in patients with stable (ST) cirrhosis and acute decompensation (AD). (A) Adhesion of normal platelets in the
presence of plasma of healthy controls or patients. Platelet adhesion activity of plasma from patients with cirrhosis was studied using
reconstituted blood at 1,800/s, 2.5 minutes using a cone and plate analyser with uncoated wells (DiaMed Impact-R). Ten ST, 10 AD patients and
10 controls were selected. The number of platelets (Plt) adhering were determined by acid phosphatase activity. Results of cirrhotic samples are
separated according to the absence or presence of ultra-large molecular weight multimers (ULMWM). Lines denote median values. p-Values were
calculated by Mann–Whitney and Kruskal–Wallis H tests. (B) Thrombin generation in plasma of controls and both cirrhotic patient groups.
Samples from 31 controls, 62 ST and 27 AD cirrhotic patients were analysed using the Technothrombin kit and results are expressed as peak
thrombin concentration. Lines denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the 5th to 95th range.
p-Values were calculated by Kruskal–Wallis H test with Dunn’s multiple comparison post hoc analysis.
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(223–293) nM in ST (n ¼ 62) and 362 (242–440) nM in AD
(n ¼ 27) patients.
Association of VWF:CB, ADAMTS13 Activity and CRP
with Survival
Within the ST group 4 out of 99 patients, whereas in the AD
group 17 out of 54 patients died. The causes of death were
liver-related in all patients, namely, GI bleeding in 3 patients,
infection in 11 patients and hepatorenal syndrome in 7
patients. The areas under the ROC curves to predict 6-month
survival (►Fig. 7A) were 0.708 (95% CI, 0.629–0.778) for VWF:
Ag level, 0.717 (95% CI, 0.639–0.787) for VWF:CB level and
0.612 (95% CI, 0.530–0.6 90) for ADAMTS13 activity. The
optimum cut-offs for predicting poor 6-month survival
according to the Youden index were VWF:CB activity > 245%
with 80.95% sensitivity and 58.33% speciﬁcity and ADAMTS13
activity < 50% with 47.62% sensitivity and 82.44% speciﬁcity.
Patients with either > 245% VWF:CB activity, or < 50%
ADAMTS13 activity or > 10 mg/L CRP level had signiﬁcantly
poorer 6-month survival. The 6-month survivals were 74.6%
versus 94.4% in patients according to the VWF:CB activity
(►Fig. 7B), 69.2% versus 89.5% according to the ADAMTS13
activity (►Fig. 7C) and68.9%versus92.3%according to theCRP
level (►Fig. 7D). Within the AD group, 6-month survivals
were 60.1% versus 80.8% for VWF:CB activity, 57.2% versus
72.0% according to the ADAMTS13 activity and 55.7% versus
78.6% for CRP levels. Within the AD group, these survivals
showed high numerical difference, but due to the low number
of patients, these data did not reach statistical signiﬁcance.
Discussion
In this study, we performed detailed analyses of both VWF
and ADAMTS13 in one of the largest group of patients with
cirrhosis, published so far. We have tried to clarify hitherto
unanswered questions in our study. Namely, (1) what is the
effect of AD and systemic inﬂammation in patients with
cirrhosis on VWF parameters including multimer distribu-
tion as well as ADAMTS13 activity as compared to patients
with stable cirrhosis; and (2) can the presence of a pro-
thrombotic state be conﬁrmed in these patients?
It is known that VWF:Ag levels are highly elevated in
patients with cirrhosis.33,34 Several previously published
data provide strong evidence that the level of VWF:Ag is
related to the severity of the disease, reaching the highest
levels in Child C patients. The platelet glycoprotein Ib binding
Fig. 7 Survival of cirrhotic patients. Receiver operating characteristics curves for prediction of 6-month survival for von Willebrand factor
antigen (VWF:Ag) (dotted line), VWF collagen-binding activity (VWF:CB) (solid line) and a disintegrin-like and metalloproteinase with
thrombospondin type-1 motifs 13 (ADAMTS13) activity (dashed line), indicating the best nominal area under the curve (AUC) for VWF:CB (A).
Kaplan–Meier curves indicate higher 6-month survival for patients with < 245% VWF:CB (B), or with > 50% ADAMTS13 activity (C) or < 10mg/L
C-reactive protein (CRP) level (D).
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functional capacity of VWF, a feature that is measured by
VWF:RCo, is also substantially elevated, albeit not to the
same extent as the VWF:Ag level.3,35
We could demonstrate that VWF:CB activity, which mea-
sures the binding capacity of VWF to collagen, was even higher
than the VWF:RCo as we show here for the ﬁrst time. Our
ﬁnding is in contrast to the previous publications of Lisman’s
group. As they observed, VWF:CBwas lower in any type of liver
diseases than in controls,3,36,37 despite that this activity ismore
sensitive to the presence of high multimers than the VWF:
RCo.38 There was, however, a major difference between their
and themethodology thatweandothers areusing.OurVWF:CB
measurements were done in parallel to the VWF:Ag measure-
ments from the same sample dilutions. Lisman et al, however,
added the same amount of VWF:Ag into the wells (5% and 2.5%
of the amount ofVWFpresent in pooled normal plasma) for the
determinationof theVWF:CB,hence theirdatabetter reﬂect the
VWF:CB/VWF:Ag ratio, which also in our hands was reduced.
Moreover, they demonstrated that plasma frompatients either
with cirrhosis or acute liver failure inducedan increasedplatelet
adhesion to collagen surface,which deﬁnitively suggests awell-
functioningVWF:CBactivity. Theseadhesion results underﬂow
conditions could further conﬁrm our ﬁndings.
The relative decrease of VWF:RCo and VWF:CB suggests a
signiﬁcant qualitative alteration of the multimeric structure
of VWF. Indeed, we could demonstrate two major types of
changes in the multimeric structure of VWF. In the majority
of cirrhotic patients, where ULMWM was not present, the
relative ratio of the LMWM fractionwas increased, while the
ratio of the haemostatically most active HMWM was
reduced, that is, a shift from HMWM to LMWM could be
observed. Remarkably, the absolute quantity of VWF within
LMWM showed a threefold and in the HMWMonly a twofold
increase as compared to controls. Another major change
could be seen in almost 50% of the AD patients where the
presence of ULMWM of VWF could be detected. In these
patients, the relative ratio as well as the absolute quantity of
VWF:Ag within the HMWM fraction was much higher than
in AD patients without ULMWM. Furthermore, wemeasured
both lower activity and antigen levels of the VWF-cleaving
protease ADAMTS13. In contrast, in patients without
ULMWM, ADAMTS13 levels were similar to controls. Hence,
in the group of patients with advanced liver cirrhosis, we
suggest that probably the primary step is a decrease in
ADAMTS13, whichmight be the consequence of the AD event
combined with the systemic inﬂammation, represented by
the higher CRP. Within the AD patient group ACLF represents
an even more severe disease, in this minor group we found
thehighest VWF:Ag level and ADAMTS13was also low. These
ﬁndings are in line with previous results.39
We put forward for consideration on the one hand, an
ADAMTS13 independent alteration of VWF in those mostly
stable cirrhotic patients in whom ADAMTS13 level is normal
and ULMWM are not present. In these patients, degradation
of VWFmultimers may be due to other proteolytic enzymes,
like plasmin40 or other serine proteases.41On the other hand,
in the most advanced cirrhotic patients ULMWM can be
detected due to the low level of ADAMTS13. The signiﬁcantly
increased VWF activity in cirrhotic plasmas containing
ULMWM was conﬁrmed by our platelet adhesion experi-
ment. Our results suggest that indeed in the most severe
cirrhotic patients a pro-thrombotic state can develop, to
some extent reminiscent towhat happens in TTP.8 Infections
as well as systemic inﬂammation are supposed to induce a
pro-thrombotic tendency in cirrhotic patients. This was
proved by several lines of evidence, such as elevation of
coagulation factor VIII or VWF levels and platelet activation
due to gut-derived endotoxins; or demonstration of
increased thrombin generation.16,18,39,42–45 Our observa-
tions are in line with these previous studies, since we could
demonstrate increased platelet adhesion together with
increased thrombin generation in half of our AD patients.
ADAMTS13 is secreted by hepatic stellate cells,10 which
are known to be activated in cirrhotic patients.11 We spec-
ulate that in AD the synthesis of ADAMTS13 is reduced, since
inﬂammatory cytokines are known to inhibit ADAMTS13
synthesis by the stellate cells.46 Furthermore, as the half-life
of ADAMTS13 is about 2 to 3 days,47 the ULMWM can appear
within a couple of days. In patients with AD, the very low
ADAMTS13 activity together with the presence of ULMWM
might represent an already signiﬁcantly advanced disease
stage. From these data, we can propose that multimeric
analysis of VWF and ADAMTS13 activity measurement,
albeit that they are not routine tests, could help to identify
patients with a pro-thrombotic tendency. As standardized
ADAMTS13 activity measurement, a WHO international
standard and quality controls are available, we propose to
measure ADAMTS13 activity especially in those centres
where care is taken of the most advanced patients.
The severity of these events is clearly demonstrated by the
poor 6-month survivals of these patients. Higher VWF:CB
activity (> 245%), higher CRP (> 10 mg/L) as well as low
ADAMTS13 activity (< 50%) either in the total group of
patients or within the patients with AD resulted in higher
mortality. Systemic inﬂammation together with the activa-
tion of the haemostatic system can play a role in the disease
progression and this raises the need for thromboprophylaxis
in these patients. Villa et al could demonstrate that low
molecular weight heparin did prevent portal vein thrombo-
sis and delayed hepatic decompensation.43 No data are
available at present for antiplatelet prophylaxis.
Thereare somecontroversies on themultimeric structureof
VWF as well as ADAMTS13 levels in cirrhotic patients categor-
ized by the Child-Pugh system. Lisman et al suggested that
there are less HMWM compared to controls and very variable
ADAMTS13 levels.3 Uemura et al were the only ones who
categorized the patients according to three different multi-
meric patterns,35 and LMWM dominated in the ﬁrst group. In
the second group, normal multimeric structure was demon-
strated,whereas in the third one, the presence of ULMWMwas
detected. They showed a negative correlation between
ADAMTS13 levels and the severity of cirrhosis and suggested
an increased intra-hepatic formation of micro-thrombi. How-
ever, more than 50% of the Japanese patients (57/109) suffered
also from hepatocellular carcinoma which signiﬁcantly
increased the heterogeneity of their patients. In another study,
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Reuken et al investigated the effect of systemic inﬂammation,
mostly due to bacterial infections, on VWF.44 Both VWF levels
as well as ADAMTS13 levels were very similar to our ﬁndings,
but they could not demonstrate any change in the multimeric
structure of VWF. They used, however, throughout their study,
1.6% SDS-agarose gel electrophoresis. As a consequence, the
migration of the large multimers from the stacking gel into
the separating gel was most probably less complete than into
the 0.8 or 0.65% agarose gels we used, which therefore seems
to be more sensitive to identify the changes of the multimeric
structure of VWF, especially the ULMWM.
In summary, we here for the ﬁrst time demonstrate, that
VWF:CB activity measurement has similar value as VWF:RCo
determination in cirrhosis. Also, we could quantitatively
demonstrate that the ratio of the LMWM was signiﬁcantly
increased in stable cirrhotic patients. Furthermore, in themost
severe cirrhotic patients with AD signiﬁcantly reduced
ADAMTS13 activity could be found, along with the presence
of ULMWM, which are markers of thrombotic micro-angio-
pathy and possible contributors to the disease progression.
What is known about this topic?
• High von Willebrand factor (VWF) level and ristocetin
cofactor activity are present in cirrhosis that counter-
balance low platelet count.
• ADAMTS13 activity is low in advanced cirrhosis.
• There are controversies on the multimeric structure of
VWF in cirrhosis.
What does this paper add?
• Collagen-binding activity was similarly elevated as
ristocetin co-factor activity and was strongly corre-
lated with VWF antigen in cirrhosis.
• The ratio of low molecular weight VWF multimers
increased and that of the high multimers decreased in
stable cirrhosis.
• Ultra-large VWFmultimers and the lowest ADAMTS13
activity together with increased thrombin generation
were evidenced in patients with acute decompensa-
tion resulting in increased pro-thrombotic activity.
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